Streetbeat News

NVO

Novo Nordisk A/S

https://www.novonordisk.com

Industry

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Open

101.67

Mkt cap

459B

Volume

7.8M

High

102.34

P/E Ratio

33.91

52-wk high

148.15

Low

100.32

Div yield

0.01

52-wk low

94.73

Disney is considering different strategies for its Star India business, which could include partnering with another company or even selling it. Kim Kardashian is reportedly in negotiations to buy back the minority stake in her beauty company, SKKN BY KIM, from Coty Inc. KPMG is reportedly looking to invest around $2 billion in AI and cloud services across its global business lines over the next five years. CVS's Caremark business experienced a halt in prescription processing. Ark Invest sold 135,152 shares of Coinbase Global Inc. Faraday Future Intelligent Electric flagged errors in its previously issued financial statements. The European Commission has fined Illumina Inc and Grail Inc for implementing their proposed merger before approval. Activision Blizzard Inc stock is trading lower amid reports of a possible new investigation on the Microsoft Corp takeover deal. Broadcom Inc won conditional approval from the European Commission to complete its acquisition of VMware. Domino's Pizza Inc entered a new global agreement with Uber Technologies Inc. Takeda Pharmaceutical Co Ltd is voluntarily withdrawing its marketing application for its dengue vaccine. Google quietly ditched its AI-powered mobile chatbot app, Bubble Characters. Warren Buffett's Berkshire Hathaway stood to make a profit of over $1 billion following the court's decision to allow Microsoft Corp to proceed with its acquisition of Activision Blizzard. IBM is weighing the use of artificial intelligence chips designed in-house to lower the costs of operating a cloud computing service. Novo Nordisk A/S's weight-loss drug, Wegovy, saw a significant drop in adherence compared to what was reported in clinical trials. Microsoft Corp has revealed that a China-based hacking group, Storm-0558, breached email accounts linked to government agencies in Western Europe. Hyundai Motor Company unionized workers at its plants across South Korea reportedly staged the first strike in five years against the government's labor policies.

Portfolio Pulse from Vandana Singh

July 12, 2023 | 1:48 pm

A study reveals that only 32% of patients prescribed Novo Nordisk's weight-loss drug, Wegovy, were still using the medication a year after their initial prescription, indicating a significant drop in adherence. The average annual cost of care for patients increased by 59% after starting the medication. The study was conducted by Prime Therapeutics, a pharmacy benefits manager, reviewing data for 4,255 people. NVO shares are up 0.71% at $153.33 during the premarket session on the last check Wednesday.

Portfolio Pulse from Vandana Singh

July 12, 2023 | 12:14 pm

The European Union’s drug regulator has expanded its investigation into the risk of suicidal thoughts and self-injury among patients taking weight loss and diabetes medications, including those produced by Novo Nordisk. The probe could potentially involve Eli Lilly‘s diabetes drug Mounjaro and similar products under development by Pfizer and Amgen. The investigation could potentially establish new side effects associated with blockbuster drugs such as Wegovy and Ozempic.

Portfolio Pulse from Benzinga Newsbot

July 12, 2023 | 2:33 am

The article reports on the options activity of 10 health care stocks in today's session. The stocks include Tilray (TLRY), Teva Pharmaceutical Industries (TEVA), BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ), Merck & Co (MRK), Tenet Healthcare (THC), CVS Health (CVS), Novo Nordisk (NVO), iRhythm Technologies (IRTC), and Danaher Corporation (DHR). The article provides detailed information on the type of options activity (put/call), trade type, sentiment, expiration date, strike price, total trade price, open interest, and volume for each stock.

Portfolio Pulse from Benzinga Insights

July 11, 2023 | 5:39 pm

Novo Nordisk's shares are trading lower following a report that most patients using weight loss drugs like Wegovy stop within a year.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 4:03 pm

The European Medicines Agency has extended its review of Novo's drugs Ozempic, Saxenda, and Wegovy, which started on 3 July 2023, to include other GLP-1 receptor agonists.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 3:47 pm

Novo Nordisk will launch its weight-loss drug Wegovy in Germany using a different injection pen to avoid impacting U.S. supplies. The company faced production issues and high demand after launching the drug in the U.S. in June 2021. The launch in Germany is expected to have limited impact due to a German law that bans public insurance schemes from paying for weight-loss drugs.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 2:11 pm

Several stocks are recording losses in today's pre-market trading session. These include Viridian Therapeutics, VOXX International, Iovance Biotherapeutics, Equitrans Midstream, Allego, Nayax, JetBlue Airways, Novo Nordisk, and Alcoa Corporation. The reasons for the declines vary from disappointing quarterly results to downgrades by research firms.

Portfolio Pulse from Lisa Levin

July 11, 2023 | 11:21 am

Ginkgo Bioworks has announced the completion of the pilot phase of its partnership with Novo Nordisk. The partnership was previously announced and is now moving into its next phase.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 11:04 am

The weight-loss drug Ozempic, popularized in the U.S. by celebrities, is being eyed with concern in the U.K. due to its off-label use and potential side effects. The surge in Ozempic’s popularity in the U.S. has led to shortages and raised concerns about its off-label use for weight loss. The U.S. FDA has stated that any use of Ozempic outside of diabetes treatment would be considered ‘off-label’ use, a situation that could potentially replicate in the U.K.

Portfolio Pulse from Benzinga Newsbot

July 11, 2023 | 2:49 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.